# The Relative Efficacy of Monotherapies for Palmoplantar Pustulosis and Palmoplantar Psoriasis: A Network Meta-Analysis Study of the Palmoplantar Spectrum

## TL;DR

This study compares the effectiveness of different treatments for palmoplantar pustulosis and psoriasis using advanced statistical analysis.

## Contribution

The paper provides a network meta-analysis of monotherapies for palmoplantar spectrum disorders using Bayesian methods.

## Key findings

- Ixekizumab and brodalumab (IL-17 inhibitors) showed high efficacy in treating palmoplantar pustulosis.
- Guselkumab (IL-23 inhibitor) and spesolimab (IL-36 inhibitor) also demonstrated effectiveness.
- Results were derived from 20 trials involving 2030 patients across multiple endpoints.

## Abstract

Background and Objectives: Palmoplantar pustulosis (PPPust) and palmoplantar psoriasis (PPso) are distinct palm/sole dermatoses that have historically shared the abbreviation “PPP”. Though the two—since the advent of advanced biotechnology—are now deemed separate diagnoses, each still falls under the ‘palmoplantar spectrum’. It is important to note that PPso and PPPust are each distinct from generalized pustular psoriasis (GPP), a condition that is outside the scope of our study. We quantified the relative efficacy of biologic and small-molecule monotherapies on the palmoplantar spectrum using Bayesian network meta-analyses (NMAs). Materials and Methods: On 6 November 2025, we searched PubMed, Scopus, ClinicalTrials.gov, and citations (i.e., citation mining) for randomized trials of monotherapy reporting PPP Area and Severity Index (PPPASI) outcomes at 12 or 16 weeks; we secondarily investigated fresh pustule-related outcomes at 4 weeks. We ran Bayesian NMAs with uniform priors; nodes were defined by dose and timepoint. Interventions’ Surface Under the Cumulative Ranking Curve (SUCRA) values were computed; pairwise effects with 95% credible intervals were also estimated. Sensitivity analyses adjusted for diagnosis (pustulosis vs. psoriasis) via network meta-regression. Results: Twenty trials (n = 2030) with 23 active comparators provided data for 10 endpoints (fresh pustules at 4 weeks; PPPASI-50/75 and mean percentage and absolute PPPASI change at 12 and 16 weeks). Conclusions: The NMA indicates efficacy of ixekizumab and brodalumab (IL-17 inhibitors), guselkumab (IL-23 inhibitor), and spesolimab (IL-36 inhibitor) in managing palmoplantar pustulosis.